ArQule Announces Preclinical Data Demonstrating Potential of Miransertib
21 Oct 2019 //
BUSINESSWIRE
Miransertib Granted FTD for PIK3CA-Related Overgrowth Spectrum
13 Sep 2018 //
BUSINESSWIRE
21 Oct 2019 //
BUSINESSWIRE
13 Sep 2018 //
BUSINESSWIRE